Detalhe da pesquisa
1.
Measuring ovarian toxicity in clinical trials: an American Society of Clinical Oncology research statement.
Lancet Oncol
; 24(10): e415-e423, 2023 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-37797647
2.
Overall survival in patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer treated with a cyclin-dependent kinase 4/6 inhibitor plus fulvestrant: a US Food and Drug Administration pooled analysis.
Lancet Oncol
; 22(11): 1573-1581, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34656225
3.
US Food and Drug Administration regulatory updates in neuro-oncology.
J Neurooncol
; 153(3): 375-381, 2021 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-34156585
4.
CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis.
Lancet Oncol
; 21(2): 250-260, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31859246
5.
U.S. FDA Drug Approvals for Gynecological Malignancies: A Decade in Review.
Clin Cancer Res
; 28(6): 1058-1071, 2022 03 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34711631
6.
U.S. FDA Drug Approvals for Breast Cancer: A Decade in Review.
Clin Cancer Res
; 28(6): 1072-1086, 2022 03 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34711632
7.
Model Development of CDK4/6 Predicted Efficacy in Patients With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced or Metastatic Breast Cancer.
JCO Clin Cancer Inform
; 5: 758-767, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-34297598
8.
Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Prior Therapies Work Group.
Clin Cancer Res
; 27(9): 2408-2415, 2021 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33563637
9.
FDA Approval Summary: Tucatinib for the Treatment of Patients with Advanced or Metastatic HER2-positive Breast Cancer.
Clin Cancer Res
; 27(5): 1220-1226, 2021 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33055172
10.
FDA Approval Summary: Palbociclib for Male Patients with Metastatic Breast Cancer.
Clin Cancer Res
; 26(6): 1208-1212, 2020 03 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31649043
11.
FDA Approval Summary: Ado-Trastuzumab Emtansine for the Adjuvant Treatment of HER2-positive Early Breast Cancer.
Clin Cancer Res
; 26(16): 4180-4185, 2020 08 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32217612
12.
Outcomes of Older Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-Negative Metastatic Breast Cancer Treated With a CDK4/6 Inhibitor and an Aromatase Inhibitor: An FDA Pooled Analysis.
J Clin Oncol
; 37(36): 3475-3483, 2019 12 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-31560580
13.
US Food and Drug Administration Pooled Analysis to Assess the Impact of Bone-Only Metastatic Breast Cancer on Clinical Trial Outcomes and Radiographic Assessments.
J Clin Oncol
; 36(12): 1225-1231, 2018 04 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-29522361
14.
National Cancer Institute Breast Cancer Steering Committee Working Group Report on Meaningful and Appropriate End Points for Clinical Trials in Metastatic Breast Cancer.
J Clin Oncol
; 36(32): 3259-3268, 2018 Nov 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-30212295
15.
Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer.
J Clin Oncol
; 23(12): 2726-34, 2005 Apr 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-15837987
16.
FDA Approval of Palbociclib in Combination with Fulvestrant for the Treatment of Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer.
Clin Cancer Res
; 22(20): 4968-4972, 2016 Oct 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-27407089
17.
First FDA approval of neoadjuvant therapy for breast cancer: pertuzumab for the treatment of patients with HER2-positive breast cancer.
Clin Cancer Res
; 20(21): 5359-64, 2014 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-25204553
18.
Contralateral breast cancer: where does it all begin?
J Clin Oncol
; 23(21): 4585-7, 2005 Jul 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-15837973
19.
Inflammatory breast cancer: dynamic contrast-enhanced MR in patients receiving bevacizumab--initial experience.
Radiology
; 244(3): 727-35, 2007 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-17709827
20.
Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer.
J Clin Oncol
; 24(5): 769-77, 2006 Feb 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-16391297